Atea Pharmaceuticals, Inc. (AVIR)

Stated as a priority in 2 of last 2 quarters. Management initiated the Phase 1 clinical trial for AT-587 in mid-2026 as planned, advancing the program targeting hepatitis E virus treatment in immunocompromised patients. This reflects delivery on the stated clinical development timeline.

Stated as a priority in 2 of last 2 quarters. Cash and investments decreased from $301.8 million at 2025-Q4 to $219.5 million at 2026-Q2, reflecting cash burn during clinical development. Management maintains that the cash runway extends through 2027, indicating ongoing capital discipline but a declining cash balance consistent with operational spending.

consolidated · GAAP

FY2026-Q2 · Period ending Jun 30, 2026

Source: company_financial_results. Reference: 287ddafa-611b-4915-886e-032b66f1d83e.

Source status: eligible.

Stated as a priority in 2 of last 2 quarters. Cash and investments decreased from $301.8 million at 2025-Q4 to $219.5 million at 2026-Q2, reflecting cash burn during clinical development. Management maintains that the cash runway extends through 2027, indicating ongoing capital discipline but a declining cash balance consistent with operational spending.

Stated as a priority in 2 of last 2 quarters. The C-BEYOND Phase 3 trial enrolled over 880 patients and achieved a 93.9% SVR rate versus 94.8% for the comparator regimen, meeting its primary endpoint. The second Phase 3 trial, C-FORWARD, completed enrollment with topline results expected early 2027. Management is delivering on the commitment to report pivotal Phase 3 topline results as scheduled.